Cargando…
The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review
Purpose: Immune checkpoint inhibitor (ICI) use can lead to immune-related adverse events (irAEs) that require treatment with immunosuppressive medications in moderate to severe cases. Oncology society guidelines recommend systemic steroids and immunosuppressants such as infliximab and vedolizumab fo...
Autores principales: | Machado, Antonio Pizuorno, Ratliff, Hunter, Abdelwahab, Ahmed, Vohra, Muhammad H., Kuang, Andrew, Shatila, Malek, Khan, Muhammad Ali, Shafi, Menhaz A., Thomas, Anusha S., Philpott, Jessica, Alhalabi, Omar, Wang, Yinghong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583582/ https://www.ncbi.nlm.nih.gov/pubmed/37859810 http://dx.doi.org/10.7150/jca.87335 |
Ejemplares similares
-
Colon Adenoma After Diagnosis of Immune Checkpoint Inhibitor-mediated Colitis
por: Machado, Antonio Pizuorno, et al.
Publicado: (2023) -
Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer
por: Liu, Cynthia, et al.
Publicado: (2023) -
Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitors
por: Panneerselvam, Kavea, et al.
Publicado: (2022) -
Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis
por: Badran, Yousef R, et al.
Publicado: (2023) -
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance
por: Verheijden, Rik J., et al.
Publicado: (2023)